The Food and Drug Administration (FDA) just announced that over 580,000 bottles of blood pressure medications made by Teva Pharmaceuticals USA and distributed by Amerisource Health Services have been recalled after it was discovered that they might contain a cancer-causing chemical.

Regular blood pressure monitoring plays an important role in maintaining heart health, yet many individuals find it difficult to do consistently. Traditional upper-arm monitors can be uncomfortable or inconvenient,

More than half a million bottles of blood pressure medication are being recalled over a cancer-causing chemical connected to the prescription drug, according to the U.S. Food and Drug Administration.

Dr Levine highlighted the often-overlooked symptoms of hypertension or high blood pressure. But can you guess what the most common symptom of hypertension is?

The FDA says more than 580,000 bottles of a blood pressure medication have been recalled over concerns that it may contain a cancer-causing chemical.

Teva Pharmaceuticals USA, based in Parsippany, New Jersey, issued a voluntary recall on Oct. 7 for some of the prazosin hydrochloride capsules it distributed. The FDA classified it as a Class II risk level on Oct. 24.

BP plc (BP.L) has stopped importing oil for its refinery in Western Australia, the country's largest, and is on track to decommission the plant by the end of March, a spokesman said on Tuesday.

Omron Evolv Wireless Blood Pressure Monitor ($60): The portable monitor provides precise clinical readings and features a built-in display that conveniently shows your results. Through Bluetooth connectivity, the Omron BPM effortlessly syncs with your Apple Watch via the Omron Connect mobile app.

Leadership, Legacy, and Lifelong Lessons in Family, Business, and Sport” by Dr. Beh Chun Chuan is released with Forbes Books.

Once the sale is completed, BP's U.S. onshore oil and gas business, bpx energy, will hold a 51% stake in the Permian assets and 25% in the Eagle Ford assets. BP is scheduled to report third-quarter results on November 4.

The drugmaker issued the recall voluntarily after determining higher-than-acceptable levels may be present in some products.